2 Strategies Traders Are Jumping On


Yesterday, Pfizer (PFE) delivered something you’ll rarely see: Its March 20 $29 put had the highest unusual options activity on the day with a Vol/OI (volume-to-open-interest) ratio of 210.16, 35% higher than the Alphabet (GOOG) option in second place.

Pfizer is one of the most frustrating stocks for bulls. Once upon a time, it was printing money thanks to COVID-19. Now, it can’t get out of the $20s. Its shares are down 59% since the 2021 all-time high of $61.71. For those who don’t own PFE, it’s hard to justify the investment.

This is where options come in.

As I said, the March 20 $29 put had a Vol/OI ratio of 210.16, representing volume of 30,263 and an open interest of 144. Somebody was willing to make a big bet on the $144 billion market cap.

When I consider what to write about when discussing unusual options activity, I rarely choose the stock with the highest Vol/OI ratio. It just seems too obvious. In this instance, however, two options strategies immediately came to mind. Here’s why.

Have an excellent weekend. Go Indiana!

In addition to the March 20 $29 put, Pfizer had two other unusually active options yesterday.

While the other two had Vol/OI ratios that qualify as unusually active, I couldn’t ignore the jump in volume for the March 20 put. You’ll notice that $29 call had the same expiration date and similar volume. These two options underlie a Long Straddle, which I will address.

In the meantime, let’s consider Pfizer’s options history.

Its 30-day average options volume is 142,695. Yesterday, it was 1.39 times that amount, and the highest volume since Dec. 17. However, it wasn’t close to the highest volume in the past three months, which was 890,898, more than six times higher than Thursday.

With earnings expected to be released on Feb. 3, it’s probably too early for a volume buildup. The 890,898 in daily volume was on the second trading day after it reported its Q3 2025 results on Nov. 4, and it also saw options volume of 376,442 on the day of the earnings release.

On Dec. 16, before the markets opened, Pfizer reaffirmed its 2025 guidance and provided modest 2026 guidance, with adjusted earnings per share of $2.90 at the midpoint, down from $3.08 in 2025. The shares fell for two consecutive days after the news, then traded primarily in a tight range between $25 and $25.50.



Source link

Leave a Reply

Your email address will not be published. Required fields are marked *